Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Statistics
  • Help & Advice
University of Warwick

The Library

  • Login

CGRP receptor antagonists: design and screening

Tools
- Tools
+ Tools

Poyner, David R., Hay, Debbie L. and Conner, Alex C. (2009) CGRP receptor antagonists: design and screening. EXPERT OPINION ON DRUG DISCOVERY, 4 (12). pp. 1253-1265. ISSN 1746-0441

Full text not available from this repository.
Official URL: http://dx.doi.org/10.1517/17460440903413496

Abstract

Importance of the field: Calcitonin gene-related peptide (CGRP) receptor antagonists have recently come to attention with the development of olcegepant and telcagepant for the treatment of migraine. The availability of high-affinity, non-peptide antagonists opens the way for trials of these compounds in other conditions where CGRP antagonism might be useful, such as septic shock and inhibition of angiogenesis. Areas covered in this review: This review summarises knowledge about the structure and signalling properties of the CGRP receptor. The clinical ramifications of targeting the CGRP receptor, the profiles of existing antagonists and the requirements for screening new compounds will be discussed. What the reader will gain: Readers will gain an overview of how current non-peptide antagonists seem to bind similar epitopes contributed by both calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1), the main CGRP receptor subunits. We will discuss how current antagonists have low bioavailability, limiting their use. For selectivity at CGRP receptors, it will be necessary to target parts of the receptor influenced by both RAMP1 and CLR. Take home message: For the design of radically new antagonists, more structural information on the receptor is needed. Current screens are largely based on measuring CGRP-mediated changes in cAMP. CGRP receptors can influence other signalling pathways and pathway-selective allosteric antagonists may be useful, but more information is needed about the mechanism of action of CGRP to assess the value of this.

Item Type: Journal Item
Subjects: R Medicine > RS Pharmacy and materia medica
Journal or Publication Title: EXPERT OPINION ON DRUG DISCOVERY
Publisher: INFORMA HEALTHCARE
ISSN: 1746-0441
Date: December 2009
Volume: 4
Number: 12
Number of Pages: 13
Page Range: pp. 1253-1265
Identification Number: 10.1517/17460440903413496
Publication Status: Published
URI: http://wrap.warwick.ac.uk/id/eprint/16732

Data sourced from Thomson Reuters' Web of Knowledge

Request changes to a record

Actions (login required)

View Item View Item
twitter

Email us: publications@warwick.ac.uk
Contact Details
About Us